Abstract
The C3 convertases are the major proteases of the complement cascade and are assembled at the site of complement activation via several different pathways. Properdins functional role in stabilizing the alternative pathway convertase has been long established; however, new evidence demonstrates that properdin can also bind to certain microbial surfaces, and provide a platform for de novo convertase assembly. Therefore, properdin participates in two distinct mechanisms for complement activation: the alternative pathway and a properdin-directed pathway. Previous work had implicated the alternative pathway in the initiation and/or progression of several autoimmune diseases and in the host defense against certain bacterial pathogens. Those conclusions were based on evidence that cannot distinguish effects of the alternative pathway from effects of the properdin-directed pathway. With the identification of the new role for properdin in C3 convertase assembly there became a pressing need to reassess the mechanisms of complement activation, determine the specific role of properdin in each of these pathways, and explore the new therapeutic avenues that could arise.
Keywords: Properdin, complement, C3 convertase, innate immunity, Neisseria, alternative pathway, properdin-directed pathway
Current Drug Targets
Title: Properdin and Complement Activation: A Fresh Perspective
Volume: 9 Issue: 2
Author(s): Dennis E. Hourcade
Affiliation:
Keywords: Properdin, complement, C3 convertase, innate immunity, Neisseria, alternative pathway, properdin-directed pathway
Abstract: The C3 convertases are the major proteases of the complement cascade and are assembled at the site of complement activation via several different pathways. Properdins functional role in stabilizing the alternative pathway convertase has been long established; however, new evidence demonstrates that properdin can also bind to certain microbial surfaces, and provide a platform for de novo convertase assembly. Therefore, properdin participates in two distinct mechanisms for complement activation: the alternative pathway and a properdin-directed pathway. Previous work had implicated the alternative pathway in the initiation and/or progression of several autoimmune diseases and in the host defense against certain bacterial pathogens. Those conclusions were based on evidence that cannot distinguish effects of the alternative pathway from effects of the properdin-directed pathway. With the identification of the new role for properdin in C3 convertase assembly there became a pressing need to reassess the mechanisms of complement activation, determine the specific role of properdin in each of these pathways, and explore the new therapeutic avenues that could arise.
Export Options
About this article
Cite this article as:
Hourcade E. Dennis, Properdin and Complement Activation: A Fresh Perspective, Current Drug Targets 2008; 9 (2) . https://dx.doi.org/10.2174/138945008783502458
DOI https://dx.doi.org/10.2174/138945008783502458 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Para-Nonylphenol Induces Apoptosis of U937 Human Monocyte Leukemia Cells in vitro
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Technology Development for the Biosynthesis of Human Milk Oligosaccharide
Recent Patents on Biotechnology Immunotherapy for Multiple Sclerosis: Basic Insights for New Clinical Strategies
Current Neurovascular Research Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Novel Molecular Targets for Systemic Lupus Erythematosus
Current Drug Targets Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Introduction from Editor-in-Chief
Current Rheumatology Reviews Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Deciphering the Antibodyome - Peptide Arrays for Serum Antibody Biomarker Diagnostics
Current Proteomics Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Comparative Molecular Characterization to Reveal Surface Behaviour of Non-proteolytic Bromelain Mutants
Current Pharmaceutical Biotechnology Natural Cures for Type 1 Diabetes: A Review of Phytochemicals, Biological Actions, and Clinical Potential
Current Medicinal Chemistry Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry The Role of Nitric Oxide in Autoimmune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology